EDAP TMS reported strong financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, total worldwide revenue increased 3.6% to EUR 20.3 million (USD 21.5 million), with HIFU revenue rising to EUR 8.8 million (USD 9.3 million) from EUR 7.5 million (USD 8.1 million) in Q4 2023. The company sold 11 Focal One systems and saw U.S. Focal One procedures grow by 31%.
For the full year 2024, total worldwide revenue was EUR 64.1 million (USD 69.2 million), an increase of 6.1% from 2023, and HIFU revenue increased 15.7% to EUR 23.8 million (USD 25.7 million). Gross profit margin improved to 44.8% in Q4 2024 from 43.7% in Q4 2023, and to 41.4% for the full year from 40.4% in 2023, primarily due to higher Focal One system sales.
The net loss for the full year was EUR 19.0 million (USD 20.5 million), or EUR (0.51) per share, compared to EUR 21.2 million (USD 22.9 million), or EUR (0.57) per share in 2023. Cash and cash equivalents stood at EUR 29.8 million (USD 30.9 million) as of December 31, 2024. Additionally, CMS released the physician fee schedule for 2025, providing strong HIFU reimbursement with 17.73 work RVUs and 29.41 Total RVUs, which is more than 80% of the payment for robotic radical prostatectomy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.